APTO - Aptose tumbles on updated early-stage data luxeptinib in blood cancers

coffeekai/iStock via Getty Images Aptose Biosciences (APTO) has lost ~24.5% in early hours after the company announced updates on its clinical program for luxeptinib currently undergoing two Phase 1 a/b trials in blood cancers. The oral, first-in-class FLT3 and BTK kinase inhibitor is undergoing early-stage studies targeting relapsed or refractory acute myeloid leukemia ((AML)) and relapsed or refractory B cell malignancies. In the AML trial, the company has completed the first two dose cohorts (450mg and 600mg) and has escalated to the third cohort (750mg). Further escalations of the trial are planned after seeing no unfavorable safety trends. “The first two dose cohorts delivered encouraging anti-leukemic activity in multiple patients,” Aptose said. A durable MRD-negative complete response has been observed in an FLT3-ITD AML patient who has relapsed after two allogeneic stem cell transplants, multiple lines of chemotherapy, and prior FLT3 inhibitor therapy. In B-cell malignancies, Aptose is currently treating patients at 750mg BID

For further details see:

Aptose tumbles on updated early-stage data luxeptinib in blood cancers